Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 17,410 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel sold 17,410 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the transaction, the director now owns 2,031,476 shares in the company, valued at $16,272,122.76. The trade was a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $7.77 on Tuesday. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.01 and a 52 week high of $9.48. The company has a market capitalization of $2.41 billion, a PE ratio of -11.43 and a beta of 1.10. The company has a 50 day moving average price of $8.27 and a two-hundred day moving average price of $8.02.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently bought and sold shares of AMRX. Gladius Capital Management LP bought a new stake in Amneal Pharmaceuticals in the third quarter valued at approximately $37,000. DekaBank Deutsche Girozentrale bought a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $42,000. Xponance Inc. bought a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $65,000. Quest Partners LLC bought a new stake in Amneal Pharmaceuticals in the third quarter valued at approximately $84,000. Finally, Profund Advisors LLC increased its stake in Amneal Pharmaceuticals by 8.1% in the second quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after purchasing an additional 1,680 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AMRX shares. Piper Sandler boosted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, Truist Financial boosted their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.